CORT FY2025 SEC EDGAR DEF 14A #78 of 168 in industry

Corcept Therapeutics Inc CEO pay ratio

The CEO earned $15.3M in FY2025 against median worker pay of $334,040 · Chemicals & Pharmaceuticals.

Chemicals & Pharmaceuticals peers All rankings
State
DE
Filing date
2026-04-17
Industry
Chemicals & Pharmaceuticals
Industry rank
#78/168

Data updated August 2026

Subscribe to Corcept Therapeutics Inc CEO pay filing updates (RSS)

CEO-to-worker pay ratio
46:1
Below Average (Scale: 0–1000:1)
CEO pay
$15.3M
Median worker
$334,040

Answer first

Corcept Therapeutics Inc's FY2025 CEO total of $15.3M ranks #292 of 1,423 complete filings; its 46:1 pay ratio ranks #998. Dollar rank is not ratio rank.

According to the same FY2025 complete-filing cohort used on the rankings boards (CEO total, median worker, and ratio all present). Median worker pay is $334,040. Industry placement uses the FY2025 SIC-28 peer cohort (# 78 of 168, 54th percentile - above the industry median pay ratio). Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.

Dollar rank
#292
$15.3M of 1,423 FY2025
Ratio rank
#998
46:1 of 1,423
Industry pct
54th
above the industry median pay ratio

How Corcept Therapeutics Inc ranks nationally

Corcept Therapeutics Inc CEO pay vs. every FY2025 complete filing

Total CEO compensation, the full national distribution, this company marked

$15,303,551 Top 21% higher than 79% of 1,423 companies

$0–$2,500,000: 304 companies (21%). Below this entry. $2,500,000–$5,000,000: 182 companies (13%). Below this entry. $5,000,000–$7,500,000: 208 companies (15%). Below this entry. $7,500,000–$10,000,000: 192 companies (13%). Below this entry. $10,000,000–$12,500,000: 139 companies (10%). Below this entry. $12,500,000–$15,000,000: 91 companies (6%). Below this entry. $15,000,000–$17,500,000: 88 companies (6%). This entry sits in this band. $17,500,000–$20,000,000: 54 companies (4%). Above this entry. $20,000,000–$22,500,000: 24 companies (2%). Above this entry. $22,500,000–$25,000,000: 34 companies (2%). Above this entry. $25,000,000–$27,500,000: 24 companies (2%). Above this entry. $27,500,000–$30,000,000: 16 companies (1%). Above this entry. $30,000,000–$32,500,000: 10 companies (1%). Above this entry. $32,500,000–$35,000,000: 7 companies (0%). Above this entry. $35,000,000–$37,500,000: 9 companies (1%). Above this entry. $37,500,000–$40,000,000: 6 companies (0%). Above this entry. $40,000,000–$42,500,000: 1 companies (0%). Above this entry. $42,500,000–$45,000,000: 1 companies (0%). Above this entry. $45,000,000–$47,500,000: 6 companies (0%). Above this entry. $47,500,000–$50,000,000: 27 companies (2%). Above this entry. This company $0 $50M+ every complete-filing company, bucketed by value

Each bar is a $2500K-wide band; taller bars hold more companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source SEC DEF 14A Section 953(b) disclosures, PlainCEOPay extract · FY2025

Corcept Therapeutics Inc vs. Chemicals & Pharmaceuticals peers

CEO total pay ($15.3M) against pay ratio (46:1) for Corcept Therapeutics Inc (marked) and its 3 closest same-industry peers, against the Chemicals & Pharmaceuticals industry median on both axes.

Pay + gap both highContained pay, wide gapHigh pay, contained gapBelow peer norms on both2715422.56969939.31122445615478972.819733489.541.8:143.1:144.5:145.9:147.3:1CEO total payPay ratio (CEO : median worker)Corcept Therapeutics Inc, CEO total pay: 15303551 · Pay ratio (CEO : median worker): 46:1Corcept Therapeutics IncMadrigal Pharmaceuticals, Inc., CEO total pay: 18959941 · Pay ratio (CEO : median worker): 47:1Madrigal Pharmaceuticals, Inc.Adaptive Biotechnologies Corp, CEO total pay: 9147140 · Pay ratio (CEO : median worker): 47:1Adaptive Biotechnologies CorpOrion S.A., CEO total pay: 3488971 · Pay ratio (CEO : median worker): 45:1Orion S.A.
Corcept Therapeutics Inc vs. Chemicals & Pharmaceuticals peers, plotted against the industry's $7.9M median CEO total and 42:1 median pay ratio.

Ratio bands among Chemicals & Pharmaceuticals peers

Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2025

A component-level pay breakdown is not reported in Corcept Therapeutics Inc's structured SEC pay-ratio disclosure. See our methodology →

Filing-year trail · Corcept Therapeutics Inc

Complete DEF 14A pay-ratio filings for this CIK across FY2022–2025. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).

Latest ratio
46:1
FY2025
vs prior FY
+6:1
from FY2024 40:1
CEO $ YoY
+55%
$15.3M latest
Filings shown
4
FY2022–2025
Corcept Therapeutics Inc CEO total compensation, median worker pay, and pay ratio by fiscal year from SEC EDGAR DEF 14A.
FY CEO pay Δ pay Median worker Pay ratio Δ ratio
2022 $7.4M - $276,749 27:1 -
2023 $9.3M +27% $250,469 37:1 +10:1
2024 $9.9M +5.9% $245,044 40:1 +3:1
2025 $15.3M +55% $334,040 46:1 +6:1

Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 1088856, FY2022–2025. Adjacent-year deltas only.

Industry Comparison - Chemicals & Pharmaceuticals

This Company's Ratio
46:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$15.3M
Companies in Industry
168
vs. Industry Median
Above
#78 of 168 by pay ratio in this industry View all companies in Chemicals & Pharmaceuticals →

Corcept Therapeutics Inc: MODEST · PEAK pay ratio

Corcept Therapeutics Inc's FY2025 CEO total $15.3M ranks #292 of 1,423 complete filings (higher third by dollars). the CEO earned 46× the median employee ($334,040) in FY2025.

Median employee $334,040 (ELITE-MED); MODEST · PEAK stamps put about 46 median-wage years per CEO year.

CEO Total Pay

$15.3M

FY2025 Summary Compensation, above median

Pay Ratio

46:1

Below typical

Corcept Therapeutics Inc in the higher-dollar third

Corcept Therapeutics Inc's FY2025 CEO total $15.3M ranks #292 of 1,423 complete filings (higher third by dollars). The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Corcept Therapeutics Inc's $15.3M CEO total is above the $7.9M industry median CEO pay.

Dollar rank #292 and ratio rank #998 split - treat 46:1 as a disclosure, not a fairness score. Open Chemicals & Pharmaceuticals peers.

Key Data, FY2025

Total Compensation
$15.3M
Median Employee Pay
$334,040
Pay Ratio
46:1
Filing Date
2026-04-17

Company Info

Ticker
CORT
CIK
1088856
Industry
Chemicals & Pharmaceuticals
SIC Code
2834
State
DE
View SEC filings →
SEC EDGAR DEF 14A for CIK 1088856, FY2025. Informational only, not investment advice. Verify on EDGAR.

Read our methodology - how this data is sourced, computed, and verified. Corcept Therapeutics Inc's FY2025 CEO total $15.3M ranks #292 of 1,423 complete filings (higher third by dollars).

Read with Corcept Therapeutics Inc

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps MODEST · PEAK · ELITE-MED.

Toll Brothers, Inc. · PEAK

ABS(ceo_total_comp) peer at $15.3M (Δ $15K lighter vs Corcept Therapeutics Inc); MID · ELITE-MED vs this page's MODEST · PEAK · ELITE-MED.
Kimberly Clark Corp · PEAK

ABS(ceo_total_comp) peer at $15.3M (Δ $22K heavier vs Corcept Therapeutics Inc); STEEP · PAR-MED vs this page's MODEST · PEAK · ELITE-MED.
Viatris Inc · PEAK

ABS(ceo_total_comp) peer at $15.3M (Δ $23K lighter vs Corcept Therapeutics Inc); HIGH · PAR-MED vs this page's MODEST · PEAK · ELITE-MED.
Lantheus Holdings, Inc. · PEAK

ABS(ceo_total_comp) peer at $15.3M (Δ $43K heavier vs Corcept Therapeutics Inc); MID · ELITE-MED vs this page's MODEST · PEAK · ELITE-MED.
Mannkind Corp (SIC 28 pole)

Mannkind Corp stamps MODEST · UNFILED nearest in-SIC by ABS(pay_ratio) to Corcept Therapeutics Inc's MODEST filing.
National dual ranks · #292/#998

Corcept Therapeutics Inc's FY2025 package sits #292 by CEO dollars and #998 by ratio under PEAK · MODEST.
Ratio primer · MODEST

Corcept Therapeutics Inc's MODEST stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for Corcept Therapeutics Inc (CIK 1088856), FY2025. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.